Research on Global Markets has announced the addition of “Therapeutic Class Overview: Treating Refractory Hematological Malignancies “research report to their offering. The report provides an overview of the approved therapies for rrmm, ndmm, aml, mds, unmet need and limitations of the current soc for relapsed and refractory pts.
For more information visit: http://www.researchonglobalmarkets.com/therapeutic-class-overview-treating-refractory-hematological-malignancies.html
